Nanosilver-marine fungal chitosan as antibiotic synergizers against sepsis fish bacteria.

Khouloud Mohamed Barakat, Yousri Mahmoud Gohar

Open access · greenAbstract read

In one paragraph

Article in Iranian journal of microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 43% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

Antimicrobial Actions and Applications of Chitosan.Polymers · 2021
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Khouloud Mohamed BarakatMicrobiology Lababoratoy, Marine Environment Division, National Institute of Oceanography & Fisheries.

Yousri Mahmoud GoharBotany and Microbiology Depart, Faculty of Science, Alexandria University.

National Institute of Oceanography and Fisheries · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMortality is highly variable within population of cultured fish due to virulent bacteria causing fish septicemia. The use of nano-silver marine fungal chitosan as antibiotic synergisers could be an alternative in the treatment of sepsis fish pathogens. MATERIALS AND

methodsDifferent bulk chitosan solutions were prepared from the mycelia of four marine fungi (Aspergillus terreus, Aspergillus flavipes, Tricoderma hamatum and Fennellia flavipes) and used as capping agents for silver nanoparticles. In vitro, the antibacterial activity of these preparations was determined against nine fish-sepsis causing bacteria, alone and in combination with nine antibiotics of choice used in aquaculture. Prepared fungal chitosans (CsF) were characterized by yield of chistosan obtained, degree of deacetylation and viscosity. RESULTS AND

conclusionThe maximum yield of chitosan (28%) was obtained from Aspergillus terreus. A. terreus chitosan (CsF), silver nanoparticles (AgNPs) and chitosan-silver nanoparticles (CsF-AgNPs) showed maximum activity at the minimum inhibitory concentrations average (MICAVG) 27.2, 18.2 and 7.9 μg/ml, respectively. Combination of CsF -AgNPs with amikacin (Ak) and rifampicin (RD) reduced the MIC values by 96 and 94%, respectively, with fractional inhibitory concentration index (FICI) = 0.42 and 0.50 as synergistic effect. It is promising to use CsF-AgNPs as enhancing agent in combination with antibiotics for fish sepsis therapy.

Indexed as

antibioticsbacterial sepsisMarine fungal chitosannanosilversynergy

Identifiers

PMID26885333

PMCPMC4752687

OpenAlexW2237606072

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.